Systematic review of risk factors, prognosis, and management of colorectal signet-ring cell carcinoma

Table 4 Overview of articles reporting on survival outcomes for colorectal signet-ring cell carcinoma

Report	5-yr OS (SRC vs other)	5-yr OS in stage III tumors	5-yr DFS % (SRC vs other)
Song et al[25], 2017	5-yr CSS: 85.6% (colon: 89.2%, rectum: 73.3%) vs 90.7% MA (P = 0.17) (colon: 90.5%; rectum: 91.6%) vs 93.3% AC (P = 0.013) (colon: 93.8%; rectum: 92.2%)	NA	NA
Wu et al[9], 2018	5-yr CSS: Colon: 33.2%; rectum: 28.1%	NA	NA
Hartmann et al[16], 2013	66% mucin-rich vs 19% mucin-poor (P = 0.0035); 75% MSI-H vs 48% MSS	NA	66% mucin-rich vs 0% mucin-poor (P = 0.0001); 73% MSI-H vs 31% MSS
van Oudheusden et al[59], 2015	3-yr OS: 0% vs 44%	NA	NA
Wu et al[10], 2019	26.8% vs 50.6% MA vs 60.2% OA (HR: 1.592, 95%CI: 1.558-1.627, P < 0.001)	NA	NA
Hyngstrom et al[19], 2012	NA	Relative survival: Colon IIIa: 0.81 vs 0.87 MA vs 0.86 OA; IIIb: 0.49 vs 0.66 MA vs 0.65 OA; IIIc: 0.21 vs 0.42 MA vs 0.45 OA; rectum IIIa: 0.91 vs 0.82 MA vs 0.86 OA; IIIb: 0.55 vs 0.56 MA vs 0.64 OA; IIIc: 0.3 vs 0.44 MA vs 0.48 OA	NA
Hugen et al[17], 2015	Relative survival: Colon: 31% vs 58% MA vs 57% OA; rectum: 20% vs 54% MA vs 57% OA	Relative survival: Colon: 36% vs 54% MA vs 57% OA; rectum: 25% vs 45% MA vs 54% OA	NA
Kang et al[12], 2005	26.8% vs 58.1% MA (P < 0.0001) vs 62.9% OA (P < 0.0001)	IIIa: 68.3% vs 87.3% MC vs 83.8% OA; IIIb: 46% vs 64.3% MC (P = 0.0002) vs 63.6% OA (P <0.0001); IIIc: 19% vs 29.2% MC (P <0.0001) vs 30% OA (P <0.0001)	NA
Ciarrocchi[4], 2014	32% (32% rectum vs 33% colon)	NA	NA
Huang et al[26], 2016	5-yr CSS: 52.2% (< 35 yr poorer CSS than > 35 yr, P < 0.001 at cutoff of 30 y, P < 0.001 at cutoff of 35 y, P = 0.015 at cutoff 40 yr)	NA	NA
Ling et al[50], 2017	NA	34.% vs 53.9% (MA) vs 63.1% (OA; P = 0.001)	NA
Wu et al[11], 2017	39%	NA	NA
Thota et al[30], 2014	NA	19% vs 41% MA vs 47% (P = 0.0002)	NA
Nitsche et al[33], 2013	40.3% (95%CI: 32.1-48.5) vs 58.7% (95%CI: 58.0-59.3)	NA	NA
Fu et al[58], 2016	9.66% vs 24.04% (non-SRCC)	NA	NA
Kakar and Smyrk[44], 2005	41% MSI-H vs 34% MSS (P = 0.3)	NA	NA
Sung et al[21], 2008	3-yr CSS: 33% vs 74% MA (P < 0.0001)	NA	NA
Chen et al[6], 2004	23.3 % vs 40.3% (MA) vs 54.5 % (NMA) (P < 0.001)	32.5% vs 38.3% (MA) vs 41.5% (NMA)	NA
Wang et al[43], 2016	3-yr OS: 62.7%	NA	NA
Liang et al[31], 2018	10.80%	Mean survival time in stage III tumors: 37.1 ± 3.9 (22-80) mo	NA
Lee et al[52], 2007	25.3% vs 68.6% MA vs 53.7% poorly differentiated OA (P < 0.001)	14.5% vs 61.5% MA vs 46.3% (P < 0.001)	12.3% vs 59.9% MA vs 46.8% poorly differentiated OA (P < 0.001)
Bittorf et al[8], 2004	14.7% vs 53.6% (P < 0.001)	20.8% vs 62.6%	NA
Messerini et al (1995)[32]	9.10%	NA	NA
Bademci et al[28], 2019	NA	NA	16 (47%) disease-free during follow-up
Kakar et al[45], 2012	33% vs 50% MA vs 63% (P = 0.09)	III/IV: 27% vs 43% MA vs 57% OA (P = 0.03)	NA
Chew et al[22], 2010	5-yr CSS: 11.1% (0-22.9%) vs overall 57.4% (55.4%-59.4%; P <0.001)	NA	No statistical difference (P = 0.356)
Nitsche et al[1], 2016	5-yr CSS: 21% ± 8% vs 61% ± 3% MA vs 67% ± 1% OA (P < 0.001)	5-yr CSS for stage III: 15% ± 10% vs 60% ± 5% MA vs 65% ± 2% OA (P < 0.001)	NA
Anthony et al[7], 1996	22%	NA	NA
Song et al[64], 2009	27% vs 51% MA vs 69% (P < 0.01)	NA	NA
Zhang et al[65], 2020	31.3% ± 12.9% vs 58.1% ± 7.7% (P = 0.018)	NA	NA
Wang et al[39], 2019	37.3% (95%CI: 14.4%-61.2%) vs 62.9% (95%CI: 48.5%-74.3%; P = 0.021)	NA	NA
Song et al[66], 2019	SRCC predominant MAC with worse survival (P < 0.001)	NA	NA
Mizushima et al[36], 2010	24.1% vs 77.5% well/moderately differentiated vs 57.7% poorly differentiated/MA	NA	NA
Foda et al[42], 2018	10.5% vs 23.2% MA vs 42.9% AWMC vs 55.3% OA	NA	3-yr DFS: 11.1% vs 28.3% MA vs 60.7% OA with SRC component vs 63% OA
Lee et al[29], 2015	46% vs 88.7% (P > 0.001)	NA	NA
Pozos-Ochoa et al[37], 2018	3-yr CSS: 28.6% vs 80.7% (P = 0.017) (II, III, and IV: 100%, 33%, and 0% vs 100%, 78%, and 73%, P = 0.017)	NA	NA
Sasaki et al[14], 1998	0% vs 76.5 % (3 mo-85 mo) (P < 0.0001)	NA	NA
Ooi et al[23], 2001	12%	NA	NA
Secco et al[68], 1994	0% vs 28% MA vs 45% OA	NA	NA

SRC: Signet-ring cell; SRCC: Signet-ring cell cancer; MA: Mucinous adenocarcinoma; OA: Ordinary/conventional adenocarcinoma; NMA: Non-mucinous adenocarcinoma; MSI-H: Microsatellite instability-high; MSS: Microsatellite stable; NA: Not applicable; CSS: Cause-specific survival; AWMC: Adenocarcinoma with mucinous component.